The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Polypharmacy and potentially inappropriate medication use in older patients with aggressive non-Hodgkin lymphoma (NHL) leads to inferior survival and increased treatment-related toxicities.
 
Richard Jirui Lin
No Relationships to Disclose
 
Helen Ma
No Relationships to Disclose
 
Robin Guo
No Relationships to Disclose
 
Michael L. Grossbard
Stock and Other Ownership Interests - Pfizer
Expert Testimony - Mylan; Novartis
 
Andrea B. Troxel
Leadership - VAL Health
Consulting or Advisory Role - Asubio Pharma; VAL Health
Research Funding - The Vitality Group (Inst); Weight Watchers (Inst)
Patents, Royalties, Other Intellectual Property - Patent pending for "Compositions and Methods for Treating Cutaneous T Cell Lymphoma”
Travel, Accommodations, Expenses - The Vitality Group
 
Catherine S. Magid Diefenbach
Stock and Other Ownership Interests - Gilead Sciences
Consulting or Advisory Role - Celgene; Idera; Immunogen; Immunogen; Janssen Oncology; Seagen
Speakers' Bureau - Gilead Sciences
Research Funding - Genentech (Inst); Gilead Sciences (Inst); Incyte (Inst); Janssen Oncology (Inst); Molecular Templates (Inst); Seagen (Inst)